Skip to Main Content (Press Enter)

Logo UNITO
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione

UNI-FIND
Logo UNITO

|

UNI-FIND

unito.it
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione
  1. Pubblicazioni

HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial

Articolo
Data di Pubblicazione:
2023
Abstract:
Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy-number variation (CNV) and AMNESIA panel encompassing primary resistance alterations (KRAS/PIK3CA/MET mutations, KRAS/EGFR/MET amplifications) may improve patients' selection for HER2 inhibition. Experimental design: In a post hoc analysis of JACOB on 327 samples successfully sequenced by next-generation sequencing (NGS; Oncomine Focus DNA), HER2 CNV, HER2 expression by IHC, and AMNESIA were correlated with overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) by univariable/multivariable models. Results: Median HER2 CNV was 4.7 (interquartile range, 2.2-16.9). HER2 CNV-high versus low using the median as cutoff was associated with longer median PFS (10.5 vs. 6.4 months; HR = 0.48; 95% confidence interval: 0.38-0.62; P < 0.001) and OS (20.3 vs. 13.0 months; HR = 0.54; 0.42-0.72; P < 0.001). Combining HER2 CNV and IHC improved discriminative ability, with better outcomes restricted to HER2-high/HER2 3+ subgroup. AMNESIA positivity was found in 51 (16%), with unadjusted HR = 1.35 (0.98-1.86) for PFS; 1.43 (1.00-2.03) for OS.In multivariable models, only HER2 CNV status remained significant for PFS (P < 0.001) and OS (P = 0.004). Higher ORR was significantly associated with IHC 3+ [61% vs. 34% in 2+; OR = 3.11 (1.89-5.17)] and HER2-high [59% vs. 43% in HER2-low; OR = 1.84 (1.16-2.94)], with highest OR in the top CNV quartile. These biomarkers were not associated with treatment effect of pertuzumab. Conclusions: HER2 CNV-high assessed by NGS may be associated with better ORR, PFS, and OS in a JACOB subgroup, especially if combined with HER2 3+. The negative prognostic role of AMNESIA requires further clinical validation.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Pietrantonio, Filippo; Manca, Paolo; Bellomo, Sara Erika; Corso, Simona; Raimondi, Alessandra; Berrino, Enrico; Morano, Federica; Migliore, Cristina; Niger, Monica; Castagnoli, Lorenzo; Pupa, Serenella Maria; Marchio', Caterina; Di Bartolomeo, Maria; Restuccia, Eleonora; Lambertini, Chiara; Tabernero, Josep; Giordano, Silvia
Autori di Ateneo:
BERRINO ENRICO
CORSO Simona
GIORDANO Silvia
MARCHIO' Caterina
MIGLIORE Cristina
Link alla scheda completa:
https://iris.unito.it/handle/2318/1880636
Link al Full Text:
https://iris.unito.it/retrieve/handle/2318/1880636/1458894/571.pdf
Pubblicato in:
CLINICAL CANCER RESEARCH
Journal
  • Dati Generali
  • Aree Di Ricerca

Dati Generali

URL

https://aacrjournals.org/clincancerres/article/29/3/571/716120/HER2-Copy-Number-and-Resistance-Mechanisms-in

Aree Di Ricerca

Settori (9)


LS4_12 - Cancer - (2022)

CIBO, AGRICOLTURA e ALLEVAMENTI - Farmacologia Veterinaria

CIBO, AGRICOLTURA e ALLEVAMENTI - Patologia e malattie degli animali

CIBO, AGRICOLTURA e ALLEVAMENTI - Scienze cliniche veterinarie

MEDICINA, SALUTE e BENESSERE - Epidemiologia

MEDICINA, SALUTE e BENESSERE - Oncologia e Tumori

MEDICINA, SALUTE e BENESSERE - Ricerca Traslazionale e Clinica

MEDICINA, SALUTE e BENESSERE - Trapianti e medicina rigenerativa

SCIENZE DELLA VITA e FARMACOLOGIA - Interazioni tra molecole, cellule, organismi e ambiente
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.5.0.1